ADAMTS9 and breast carcinoma: We observed significant downregulation of ADAMTS9‐AS2, WDFY3‐AS2, RP11‐295M3.4, RP11‐490M8.1, and CTB‐92J24.3 and significant overexpression of FAM83H‐AS1 in breast cancer.